RetinalGenix Technologies and RGEN Clinical Genotyping Laboratory Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
RetinalGenix Technologies (OTCQB:RTGN) and RGEN Inc. have announced a strategic partnership to advance early detection of neurodegenerative, systemic, and retinal diseases. The collaboration integrates RetinalGenix's proprietary high-resolution retinal imaging platform with RGEN's CLIA-certified DNA testing capabilities.
The partnership aims to develop predictive models for conditions including Age-Related Macular Degeneration, Glaucoma, Diabetic Retinopathy, Complex Dementia, Alzheimer's, and Parkinson's Disease. The dual-pronged diagnostic approach combines phenotypic retinal changes and DNA variants analysis to provide actionable insights for early intervention.
RetinalGenix plans to commercially deploy the combined screening tool in various healthcare settings and pursue partnerships with healthcare payers for preventative care coverage.
RetinalGenix Technologies (OTCQB:RTGN) e RGEN Inc. hanno annunciato una partnership strategica per promuovere il rilevamento precoce di malattie neurodegenerative, sistemiche e retinali. La collaborazione integra la piattaforma proprietaria di imaging retinico ad alta risoluzione di RetinalGenix con le capacità di test DNA certificati CLIA di RGEN.
La partnership punta a sviluppare modelli predittivi per condizioni quali Degenerazione Maculare Legata all’Età, Glaucoma, Retinopatia Diabetica, Demenza Complessa, Morbo di Alzheimer e Malattia di Parkinson. Il duplice approccio diagnostico combina cambiamenti retinici fenotipici e analisi delle varianti nel DNA per fornire intuizioni utili per un intervento precoce.
RetinalGenix intende commercializzare lo strumento di screening combinato in diversi contesti sanitari e perseguire collaborazioni con enti pagatori del sistema sanitario per la copertura della prevenzione.
RetinalGenix Technologies (OTCQB:RTGN) y RGEN Inc. anuncian una alianza estratégica para avanzar en la detección temprana de enfermedades neurodegenerativas, sistémicas y retinianas. La colaboración integra la plataforma de imágenes retinianas de alta resolución de RetinalGenix con las capacidades de prueba de ADN certificadas por CLIA de RGEN.
La asociación busca desarrollar modelos predictivos para condiciones como Degeneración Macular Asociada a la Edad, Glaucoma, Retinopatía Diabética, Demencia Compleja, Enfermedad de Alzheimer y Enfermedad de Parkinson. El enfoque diagnóstico dual combina cambios fenotípicos retinianos y análisis de variantes del ADN para proporcionar ideas accionables para intervención temprana.
RetinalGenix planea desplegar comercialmente la herramienta de cribado combinada en diversos entornos de atención médica y buscar asociaciones con pagadores del sector sanitario para la cobertura de cuidados preventivos.
RetinalGenix Technologies (OTCQB:RTGN)와 RGEN Inc.가 신경퇴행성 질환, 전신 질환 및 망막 질환의 조기 발견을 위한 전략적 파트너십을 발표했습니다. 이 협력은 RetinalGenix의 고해상도 망막 영상 플랫폼과 RGEN의 CLIA 인증 DNA 검사 capabilities를 결합합니다.
파트너십은 연령관련 황반변성, 녹내장, 당뇨망막병증, 복합 치매, 알츠하이머 병 및 파킨슨 병과 같은 질환에 대한 예측 모델을 개발하는 것을 목표로 합니다. 표적형 망막 변화와 DNA 변이 분석을 결합한 이중 진단 접근법은 조기 개입을 위한 실행 가능한 통찰을 제공합니다.
RetinalGenix는 결합된 선별 도구를 다양한 헬스케어 환경에서 상용화하고 예방적 치료 보장을 위해 보건의료 지불자와의 파트너십을 추진할 계획입니다.
RetinalGenix Technologies (OTCQB:RTGN) et RGEN Inc. annoncent un partenariat stratégique pour faire progresser le dépistage précoce des maladies neurodégénératives, systémiques et oculaires. La collaboration intègre la plateforme d’imagerie rétinienne haute résolution propriétaire de RetinalGenix avec les capacités de test ADN certifiées CLIA de RGEN.
Le partenariat vise à développer des modèles prédictifs pour des conditions telles que Dégénérescence Maculaire Liée à l’Âge, Glaucome, Rétinopathie Diabétique, Demence Complexe, Maladie d’Alzheimer et Maladie de Parkinson. L’approche diagnostique double combine les changements rétiniens phénotypiques et l’analyse des variantes d’ADN pour fournir des insights actionnables en vue d’une intervention précoce.
RetinalGenix prévoit de déployer commercialement l’outil de dépistage combiné dans divers contextes de soins de santé et de rechercher des partenariats avec les payeurs de soins de santé pour la couverture des soins préventifs.
RetinalGenix Technologies (OTCQB:RTGN) und RGEN Inc. haben eine strategische Partnerschaft angekündigt, um die frühzeitige Erkennung neurodegenerativer, systemischer und retinaler Erkrankungen voranzutreiben. Die Zusammenarbeit integriert die proprietäre Hochauflösung der Netzhautbildgebung von RetinalGenix mit RGENs CLIA-zertifizierten DNA-Testing-Fähigkeiten.
Ziel der Partnerschaft ist es, prädiktive Modelle für Erkrankungen wie Altersbedingte Makuladegeneration, Glaukom, Diabetische Retinopathie, Komplexe Demenz, Alzheimer-Krankheit und Parkinson-Krankheit zu entwickeln. Der zweigleisige diagnostische Ansatz kombiniert phänotypische Netzhautveränderungen mit der Analyse von DNA-Varianten, um umsetzbare Erkenntnisse für einen frühzeitigen Eingriff bereitzustellen.
RetinalGenix plant, das kombinierte Screening-Tool in verschiedenen Gesundheitsumgebungen kommerziell einzusetzen und Partnerschaften mit Kostenträgern im Gesundheitswesen für eine Kostenübernahme der Präventionsversorgung zu verfolgen.
RetinalGenix Technologies (OTCQB:RTGN) و RGEN Inc. يعلنان عن شراكة استراتيجية لتعزيز الكشف المبكر عن أمراض التنكس العصبي والمرضى الجهازية والشبكية. تتكامل الشراكة مع منصة التصوير الشبكي عالية الدقة التي تمتلكها RetinalGenix مع قدرات اختبار DNA المعتمدة من CLIA لدى RGEN.
تهدف الشراكة إلى تطوير نماذج تنبؤية لحالات مثل الاعتلال البقعي المرتبط بالعمر، glaucoma (الزَرَق)، اعتلال الشبكية السكري، الخَرف المعقد، مرض الزهايمر ومرض باركنسون. تجمع مناهج التشخيص المزدوجة بين التغيرات الشبكية الظاهرية وتحليل متغيرات DNA لتقديم رؤى قابلة للإجراء من أجل التدخل المبكر.
تعزم RetinalGenix طرح أداة الفحص المجمَّعة تجارياً في بيئات الرعاية الصحية المختلفة والسعي لشراكات مع دافعي التكاليف في الرعاية الصحية لتغطية الوقاية.
RetinalGenix Technologies (OTCQB:RTGN) 与 RGEN Inc. 宣布建立战略伙伴关系，以推动神经退行性疾病、系统性疾病和视网膜疾病的早期筛查。该合作将 RetinalGenix 的高分辨率视网膜成像平台与 RGEN 的 CLIA 认证 DNA 检测能力整合在一起。
伙伴关系旨在针对 年龄相关性黄斑变性、青光眼、糖尿病性视网膜病变、复杂性痴呆、阿尔茨海默病和帕金森病 等状况开发预测模型。双管齐下的诊断方法结合表型视网膜变化与 DNA 变异分析，提供可执行的早期干预洞察。
RetinalGenix 计划在多种医疗保健环境中商业化地部署这套联合筛查工具，并寻求与医疗支付方的伙伴关系，以覆盖预防性护理。
- Integration of advanced retinal imaging with clinical-grade DNA genotyping for enhanced disease detection
- Development of predictive models for early detection of major neurodegenerative and retinal diseases
- Potential for population-level screening and early intervention in chronic diseases
- Planned commercial deployment across multiple healthcare settings
- Company is still in developmental stage with no current commercial products
- No financial terms or timeline disclosed for the partnership
- Implementation and market adoption timeline uncertain
APOLLO BEACH, Fla. and HUNTINGTON, W.Va., Oct. 01, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneering developmental-stage company focused on ophthalmic screening, monitoring, pharmacogenetic mapping, and repurposed drug development for early detection and treatment of eye and systemic diseases, and RGEN Inc., a leader in genetic research and innovation (“RGEN”), today announced a strategic partnership to deliver game-changing advancements in the early detection and risk prediction of Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases.
By integrating advanced retinal imaging with clinical-grade DNA genotyping, the two organizations aim to accelerate the development of predictive models and facilitate population-level screening for conditions such as Age-Related Macular Degeneration (AMD), Glaucoma, Diabetic Retinopathy, Complex Dementia, Alzheimer’s Disease, and Parkinson’s Disease.
This collaboration leverages RetinalGenix’s proprietary high-resolution retinal imaging platform alongside RGEN’s CLIA-certified, high-throughput DNA testing capabilities. The dual-pronged diagnostic model aims to capture both phenotypic retinal changes and clinically relevant DNA variants, providing clinicians with actionable insights for early intervention and personalized treatment.
The partnership is believed to represent a major step forward in the field of predictive, preventive, and personalized medicine (PPPM). By combining retinal imaging and DNA testing, the collaboration offers a unique and powerful method for early detection of some of the most impactful chronic systemic and ocular diseases affecting aging populations. This integrated approach holds promise not only for improving patient outcomes but also for reducing the long-term burden on healthcare systems through earlier intervention and disease management.
Key objectives of the partnership include:
- Integrating retinal imaging and genotypic data to develop predictive models for disease risk.
- Identifying novel genetic biomarkers and phenotypic indicators linked to neurodegenerative, systemic and retinal diseases.
- Delivering clinically actionable insights for prevention and personalized care.
- Deploying a scalable, population-based screening platform for chronic diseases.
“Our collaboration allows us to harness the synergies of precision retinal imaging and state-of-the-art genetic analysis,” said Jerry Katzman, MD CEO of RetinalGenix Technologies. “This integrated approach aims to redefine how chronic and ocular diseases are detected and managed in at-risk populations.”
“The combination of RGEN’s clinical-grade genotyping and RetinalGenix’s advanced imaging brings new possibilities for both research and clinical care,” added Jaime Raijman, CEO & Co-founder of RGEN. “Together, we are paving the way for predictive, preventive, and personalized medicine.”
RetinalGenix’s next steps are expected to include the commercial deployment of a combined screening tool in primary care offices, clinics, remote and home monitoring locations and ophthalmology settings, partnerships with healthcare payers to support preventative care coverage, and future expansion of the platform to other age-related and neurodegenerative conditions.
About RetinalGenix Technologies Inc.
RetinalGenix is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas by integrating genetic screening, advanced imaging, and therapeutic development. Its proprietary High-Resolution Retinal Imaging and RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular, and metabolic systems, as well as diabetic conditions, Alzheimer’s disease, Complex Dementia, and Parkinson’s disease. RetinalGenix is also developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer’s disease/dementia.
About RGEN Inc.
RGEN Inc. is a leading innovator in genetic research and testing, providing advanced genomic solutions across clinical, forensic, and consumer applications. Through its CLIA-certified laboratories, RGEN delivers whole genome sequencing, targeted panels, and epigenetic testing with a focus on precision, accuracy, and rapid turnaround. The company’s expertise supports healthcare providers, research institutions, and population-level initiatives seeking to unlock actionable insights into hereditary risk, disease prevention, and personalized wellness.
Safe Harbor Statement
This press release contains certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” and similar expressions that are intended to identify forward-looking statements and include statements regarding delivering advancements in the early detection and risk prediction of Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases, the two organizations accelerating the development of predictive models and facilitating population-level screening for conditions such as Age-Related Macular Degeneration (AMD), Glaucoma, Diabetic Retinopathy, Complex Dementia, Alzheimer’s Disease, and Parkinson’s Disease, the dual-pronged diagnostic model capturing both phenotypic retinal changes and clinically relevant DNA variants, providing clinicians with actionable insights for early intervention and personalized treatment, combining retinal imaging and DNA testing offering a unique and powerful method for early detection of some of the most impactful chronic systemic and ocular diseases affecting aging populations, the integrated approach holding promise not only for improving patient outcomes but also for reducing the long-term burden on healthcare systems through earlier intervention and disease management, integrating retinal imaging and genotypic data to develop predictive models for disease risk, identifying novel genetic biomarkers and phenotypic indicators linked to neurodegenerative, systemic and retinal diseases, delivering clinically actionable insights for prevention and personalized care, deploying a scalable, population-based screening platform for chronic diseases, harnessing the synergies of precision retinal imaging and state-of-the-art genetic analysis, redefining how chronic and ocular diseases are detected and managed in at-risk populations, paving the way for predictive, preventive, and personalized medicine, commercial deployment of a combined screening tool in primary care offices, clinics, remote and home monitoring locations and ophthalmology settings, partnerships with healthcare payers to support preventative care coverage, and future expansion of the platform to other age-related and neurodegenerative conditions and developing therapeutic drugs for dry age-related macular degeneration (dry AMD) and Alzheimer’s disease/dementia. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to successfully complete research and further development and commercialization of Company products, the timing, cost and uncertainty of obtaining regulatory approvals for the Company’s products, the Company’s ability to protect its intellectual property, and the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Media Contacts:
RetinalGenix Technologies Inc.
Media and Investor Relations
ir@retinalgenix.com
(800) 331-5446
RGEN Inc.
info@rgeninc.com
681-500-RGEN (7436)
FAQ
What is the strategic partnership between RetinalGenix (RTGN) and RGEN Inc.?
What diseases can RetinalGenix and RGEN's combined technology detect?
How does RetinalGenix's partnership with RGEN work?
What are RetinalGenix's (RTGN) commercialization plans for this technology?
What are the main objectives of the RetinalGenix-RGEN partnership?
